Tempus AI
Built AI-queryable dataset from 50%+ of US oncologists; structural data moat. Q1 2026 revenue $348.1M (+36.1% YoY); Diagnostics $261.1M (+34.7%), Data & Applications $87M (+40.5% YoY). MRD test volume ~6,500 in Q1 (+500% YoY). 2026 guidance raised to $1.59-1.60B with first path to adjusted EBITDA breakeven (~$65M). BMS expanded multi-asset collaboration (May 14) adds neuroscience / Alzheimer's vertical to oncology anchor. Next platform expanded May 28 (ahead of ASCO 2026); Tempus Hub refresh May 27. Named TIME's 10 Most Influential Health and Life Science Companies of 2026.
Scenarios
'David' AI co-pilot inside EHR systems is wedge into $4T hospital spend. Data network effects compound — every new patient improves model. MRD +500% YoY and BMS neuroscience expansion address TAM-extension concerns.
Healthcare AI has longest regulatory cycles. Competition from Guardant/Google Health remains. EBITDA path is near-breakeven, not profitable — cash discipline still required.
Key Factors to Watch
- ●Q1 2026 revenue $348.1M (+36%); MRD tests +500% YoY; FY2026 guidance $1.59-1.60B with EBITDA ~$65M
- ●BMS expanded multi-asset collaboration (May 2026) — solid tumor oncology + neuroscience / Alzheimer's
- ●50%+ of US oncologists connected — structural data moat; Next platform expanded at ASCO 2026
- ●Named TIME's top 10 most influential health companies 2026; Hub refresh May 27
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-05-30 | 8.0 | Very Positive | Score 7.6→8.0 (are 8→9, aam 8→9). Direction crosses positive→very_positive on Q1 2026 print + BMS expansion: revenue +36% YoY to $348.1M; MRD volume +500% YoY; FY26 guidance raised to $1.59-1.60B with first path to adjusted EBITDA breakeven (~$65M). BMS collaboration extends from oncology into neuroscience / Alzheimer's — addresses prior TAM-limit concern. Two major platform launches (Hub refresh + Next expansion) demonstrate continuous deployment cadence (aam↑). Materiality gate cleared by named earnings + named expanded collaboration. |
| 2026-03-08 | 7.6 | Positive | Score 7.8→7.6 (are 9→8, dr 2→3, aam 7→8). External research cross-ref: not all $1.27B is pure AI revenue; competition from Guardant/Google Health; deep Merck AI collab |
| 2026-03-08 | 7.8 | Positive | Initial assessment from batch 8 research |
Healthcare Peers
Last researched: 2026-05-31
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.